New vaccine aims to stop stomach bug norovirus

NCT ID NCT06630117

Completed ⭐️ VACCINE ⭐️ Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new vaccine called V330 to see if it is safe and how well it triggers an immune response against norovirus, a virus that causes vomiting and diarrhea. The trial included 245 healthy adults aged 18-49 and 60-79. Participants received either the vaccine or a placebo, and researchers monitored side effects and antibody levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: V330 vaccine
What this could lead to: If successful, this could lead to a safe vaccine that protects against norovirus, a common cause of severe stomach illness.
What could go wrong: This is an early Phase 1 trial focused on safety, not yet proving the vaccine works. It is small and results may not apply to larger populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

California Clinical Trials Medical Group managed by PAREXEL ( Site 0002)

Glendale, California, 91206, United States
QPS-MRA, LLC-Early Phase ( Site 0006)

South Miami, Florida, 33143, United States
Research Centers of America ( Hollywood ) ( Site 0004)

Hollywood, Florida, 33024, United States
Velocity Clinical Research, Hallandale Beach ( Site 0003)

Hallandale, Florida, 33009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.